De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

NCT04675827 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

139

Enrollment

OTHER

Sponsor class

Stopped Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evaluate the potential solutions to overcome the issues.

Conditions

HER2-positive Breast Cancer
ER-Negative Breast Cancer
PR-Negative Breast Cancer
Node-negative Breast Cancer

Interventions

DRUG: Pertuzumab and tratuzumab fixed dose combination
DRUG: Trastuzumab emtansine

Sponsor

Jules Bordet Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]